Ask about this productRelated genes to: IL17A antibody
- Gene:
- IL17A NIH gene
- Name:
- interleukin 17A
- Previous symbol:
- CTLA8, IL17
- Synonyms:
- IL-17A, IL-17
- Chromosome:
- 6p12.2
- Locus Type:
- gene with protein product
- Date approved:
- 1993-10-25
- Date modifiied:
- 2019-04-23
Related products to: IL17A antibody
Related articles to: IL17A antibody
- T helper 17 (T17) cells are thought to play an important role in the pathogenesis of many autoimmune disorders, including multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE). However, recent studies have suggested that interleukin-17 (IL-17) may be dispensable for the induction of EAE. Here, we use an adoptive transfer model of EAE to demonstrate that an adaptive cellular source of IL-17 is absolutely required for the induction of EAE disease. We further show that B cells can regulate the transfer of EAE disease in this context. Transcriptional profiling of T17 cells in our model suggests that loss of IL-17A/F in T cells results in a lack of an IL-23 receptor (IL-23R)-driven signaling signature. Our data demonstrate the critical importance of an adaptive immune cellular source of IL-17A and IL-17F to mediate EAE and that IL-17 signaling is required for IL-23-mediated T17 cell pathogenicity. - Source: PubMed
Publication date: 2026/04/24
Ho Allen WHuang LinglinSandhu SumitiXiao ShengSgodzai MelissaUllerich EllaKrishnan Rajesh KSchnell AlexandraKuchroo Vijay K - Spinal manipulation (SM) may modulate immune and inflammatory responses in healthy and/or musculoskeletal pain populations, yet SM responses in neurodegenerative populations such as multiple sclerosis are essentially unknown. This pilot study estimated the potential effects of chiropractic thoracic SM combined with trigger point therapy on serum inflammatory cytokine/chemokine levels, neurodegeneration biomarkers, and clinical/performance-based outcomes in people with relapsing-remitting multiple sclerosis (RRMS). The goal was to inform the design of future research. - Source: PubMed
Publication date: 2026/04/08
Alanazi Murdi SMotl Robert WJones Benjamin AQu HaiyanLi PengReed William R - Some patients with psoriasis develop lupus erythematosus-like side effects after treatment with interleukin (IL)-17 inhibitors. Whether use of IL-17 inhibitors increases the risk of systemic lupus erythematosus (SLE) remains unclear. This study explores the potential relationship between use of IL-17 inhibitors and the onset of SLE. - Source: PubMed
Publication date: 2026/03/14
Deng LinglingWang HanChen ZitongLiu KangZhu JingfengZeng MingMao HuijuanWu Buyun - Birdshot chorioretinopathy (BSCR) is a rare, chronic, bilateral posterior uveitis uniquely associated with HLA-A29. Despite this genetic linkage, the immune mechanisms driving BSCR remain poorly defined. We conducted a systematic review to synthesize evidence on immune mediators in BSCR and their potential as biomarkers or therapeutic targets. - Source: PubMed
Publication date: 2026/04/23
Gao AngelZaslavsky KirillAhmed YusufRadies SilasWong DavidBallios Brian GWright ThomasChristakis PanosKaplan Alexander JBakshi NupuraChandran VinodDerzko-Dzulynsky Larissa - Combination therapy with programmed death-1 (PD-1) inhibitors and targeted therapy is a first-line treatment for advanced hepatocellular carcinoma (HCC). Patients with hyperbilirubinemia (total bilirubin > upper limit of normal) are often excluded from such regimens. This study aimed to evaluate the efficacy and safety of PD-1 inhibitor plus targeted therapy in this patient population and to identify plasma protein biomarkers associated with prognosis. - Source: PubMed
Publication date: 2026/04/07
Wang JianingPan ShidaXiong ChuyueTian JiaheWang YilinYu YingyingWang SiyuShen YingjuanYang LuoLiu XiaomengLuan JunqingJia MengdieDuan XuanxuanWang FushengMeng Fanping